Disclosures: Christina Tran: Nothing to Disclose, Christine Tien: Nothing to Disclose, Divya Ayyala: Nothing to Disclose, Rachan Narala: Nothing to Disclose, Ariel Lee: Nothing to Disclose, Brian Lee: NIAAA: Grant/Research Support, Novo Nordisk: Advisor, GSK: Advisor, DURECT: Advisor, HepaTx: Advisor, CymaBay: Consultant, Ipsen: Consultant, Siemens Healthineers: Grant/Research Support, Norah Terrault: Elseiver: Royalties or patent beneficiary, GSK: Grant/Research Support, Eiger Pharmaceuticals: Grant/Research Support, Helio Health: Grant/Research Support, Durect Corp: Grant/Research Support, ImmunoCore: Grant/Research Support, HBV Foundation: Board member, AASLD: Executive role 1537 INITIATION OF NALTREXONE IS ASSOCIATED WITH LOWER RATES OF SBP AND MORTALITY THAN ACAMPROSATE IN PATIENTS WITH DECOMPENSATED ALCOHOL-ASSOCIATED CIRRHOSIS Vinay Jahagirdar 1 Katherine Cooper 2 Deepika Devuni 2 , 1 University of Missouri Kansas City School of Medicine, 2 UMass Chan Medical School Background: Naltrexone and acamprosate are FDA-approved medications for the treatment of alcohol use disorder (AUD)
The authors noted that the synergistic effect of rifaximin and probiotics might enhance efficacy, but long-term follow-up and mechanistic studies are still needed for further validation
Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials
Zhang et al., 2020), as well as in tissues like the breast and bones (Larrosa et al., 2010), following the administration of pomegranate extract, inflammation markers such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E synthase (PTGES) were significantly reduced in the inflammatory rats
